There is one clinical trial.
We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.
Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28
Measure: Days alive without life support at day 28 Time: Day 28 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 28 Time: Day 28 after randomisationDescription: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90
Measure: Days alive without life support at day 90 Time: Day 90 after randomisationDescription: Death from all causes
Measure: All-cause mortality at day 90 Time: Day 90 after randomisationDescription: Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction
Measure: Number of participants with one or more serious adverse reactions Time: Day 14 after randomisationDescription: Number of days alive and out of hospital not limited to the index admission
Measure: Days alive and out of hospital at day 90 Time: Day 90 after randomisationDescription: Death from all causes
Measure: All-cause mortality at 1 year after randomisation Time: 1 year after randomisationDescription: Assessed by EQ-5D-5L
Measure: Health-related quality of life at 1 year Time: 1 year after randomisationDescription: Assessed by EQ-VAS
Measure: Health-related quality of life at 1 year Time: 1 year after randomisation